Table 1.
Baseline sociodemographic and clinical characteristics of medulloblastoma patients in the NOA-07 study who completed at least one valid health-related quality of life form or underwent neurocognitive testing at least once
| Baseline characteristics (n = 28) |
|
|---|---|
| Age in years at diagnosis | |
| Mean (SD; range) | 37 (10; 22–54) |
| Gender, no. (%) | |
| Male | 17 (61%) |
| Female | 11 (39%) |
| KPS, median (range) | 90 (50–100) |
| Histopathological entity, no. (%) | |
| Classic | 12 (43%) |
| Desmoplastic/nodular | 14 (50%) |
| Other | 2 (7%) |
| Molecular entity, no. (%) | |
| SHH-driven, p53wt | 18 (64.3%) |
| SHH-driven, p53mut | – |
| WNT-driven | 4 (14.3%) |
| Group 3 | – |
| Group 4 | 5 (17.9%) |
| Not available | 1 (3.5%) |
| Radiochemotherapy completed | 28 (100%) |
| Adjuvant chemotherapy received | 25 (89%) |
| Chemotherapy cycles, median (range) | 6 (0–8) |
| Disease progression, no. (%) | 5 (18%) |
| Progression-free survival in years, median (range); (n = 5) | 1.8 (1.1–4.5) |
| 5-year overall survival rate (%) | 70% |
SD standard deviation, KPS Karnofsky Performance Status